Citius Pharmaceuticals to Participate in October 2026 Investor ConferencesPRNewsWire · Oct 12, 2026
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Now Rated “Hold” by Wall Street BrokeragesDefense World · Oct 8, 2026
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial AnalysisDefense World · Sep 21, 2026
Brokerages Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00Defense World · Sep 16, 2026
Citius Pharmaceuticals to Participate in September 2026 Investor ConferencesPRNewsWire · Sep 3, 2026
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire · Aug 14, 2026Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.36 | -$0.34 | Beat |
| May 15, 2026 | $0.39 | -$0.95 | Miss |
| Feb 13, 2026 | $0.43 | -$0.38 | Miss |
| Dec 26, 2025 | -$0.43 | -$0.01 | Beat |
| Aug 12, 2025 | -$0.51 | -$0.80 | Miss |
| May 14, 2025 | -$1.08 | -$1.27 | Miss |